Introduction
Eukaryotic genes are composed by exonic (protein coding) and intronic (non-coding) regions.
Alternative splicing is a process in which pre-mRNA is cut at junction sites and the resulting exonic sequences are reconnected together in different ways to form different versions of mature messenger RNA. It has been shown that 92-94% of human genes can undergo alternative splicing (1, 2). This process plays an essential role in increasing the proteome diversity in eukaryotic organisms. For multiexon mRNAs, different splicing patterns can occur, e.g. exon skipping (an exon is either included or excluded from the mature mRNAs), alternative 5' or 3' splicing (exons are spliced in different lengths) or mutually exclusive splicing (exons are selectively spliced to be exclusively present in different splice forms).
Alternative splicing is carried out by the spliceosome, which consists of five small nuclear ribonucleoprotein particles (snRNPs), U1, U2, U4, U5, U6 and more than 150 other proteins (3) . Mutations in splicing sites or in the main components of the splicing machinery will affect the genes' splicing patterns, and potentially give rise to alternative protein products which may have different conformation, function or subcellular location. Disruption of the splicing machinery has been shown to be associated with many human diseases such as cystic fibrosis, Alzheimer disease and cancer (4) (5) (6) .
Large efforts have been put into identification of gene products generated by alternative splicing. This is a challenging task since alternative splice forms are often temporal, tissue specific and low abundant (7) . So far most work has been done starting at the mRNA level, taking use of the vast amount of public domain expressed sequence tag (EST) data as well as RNA sequencing data (8) (9) (10) (11) . ESTs or RNA-seq reads that belong to one gene are clustered together and then aligned to the genomic sequence in order to identify alternative splicing events. These efforts have resulted in many publically available alternative splicing databases. Most of them are generated by mining data from GenBank, UniGene and
SwissProt. (i) The Evidence Viewer Database (EVDB) is one of the relational databases
which support searching splice variants by sequence and gene symbol querying (12) . This database uses high quality transcripts from NCBI Genbank and RefSeq, which are then aligned to the chromosomal sequence in order to determine their exon structures. EVDB contains 81142 non-redundant human splice variants in the most recent build (completed in June 2010).
(ii) The ECgene database is an alternative splicing database which is constructed by genome based EST clustering. Splice variants in the database are assigned with different evidence levels based on the minimum number of clones used to cover the transcripts (13) .
Mass spectrometry (MS) based proteomics enables large-scale identification and quantification of proteins. The most commonly used workflow for MS based proteomics is the so-called bottom up approach or shotgun proteomics where proteins are digested into peptides to facilitate efficient MS analysis. Bioinformatic methods are then used to infer the protein level events (14) . A challenge in shotgun proteomics is the protein inference problem, which refers to the task of determining which proteins the identified peptides are derived from. The difficulty is due to that some peptides are shared by several proteins. Once the protein mixture is digested by a protease, peptides from all proteins are mixed together and the protein context of each and every peptide is lost. This will lead to ambiguities in the identification of proteins present in the sample. 
Preprocessing of MS data
The following information needs to be extracted from the MS output from database searching: protein accession id, peptide sequence and quantitative data (if available). The gene symbol is then assigned to each protein by the python script converter.py and is used to retrieve known protein splice variants from the EVDB database.
SpliceVista workflow
SpliceVista is designed to identify and visualize splice variants based on MS-identified peptides. There are four main parts of the program ( Fig.1 
Visualization module of SpliceVista
Given a gene symbol for the protein, SpliceVista (visualization.py) can generate an image that contains three panels ( peptides (6aa=<peptide length<= 40aa) that were later mapped to all splice variants. To compare with trypsin, in silico lysC digestion of human proteome, which generates on average longer peptides, was also performed yielding 447,880 unique peptides (6aa=<peptide length<= 40aa). In the simulated protease digestion, one missed cleavage was allowed only in cases of consecutive cleavage sites (KK, KR, RK, or RR for trypsin, and KK for lysC), and no cutting was done if the cleavage site was followed by Proline.
A431 human cell line proteomics data

Sample preparation
In order to exemplify the key functions of SpliceVista, it was used to analyze A431 human cell line (epidermoid carcinoma cell line, cell line number ACC 91) proteomics data. The sample preparation and mass spectrometry experiment was done in (19) . Briefly, twenty-four hours after seeding, A431 cell cultures (in duplicates) were treated with gefitinib and harvested at 2h, 6h and 24h after treatment. Controls were left untreated (duplicates at 0h).
Protein samples from A431 whole cell extraction and three subcellular fractions were then (corresponding peptides collected from five IPG gel strips) were performed using a hybrid LTQ-Orbitrap Velos mass spectrometer (Thermo Scientific) for each of the four peptide mixtures sets (whole cell, light, medium and heavy fraction). Detailed mass spectrometry analysis can be found in (19) .
Mass spectrometry data processing 
Results
Human protein isoforms with unique sequences and isoform specific peptides
To evaluate the potential and limitations of bottom up mass spectrometry based proteomics to do splice variant specific analysis, we performed a theoretical analysis. In the simulated trypsin digestion, 146,818 (18%) tryptic peptides uniquely mapped to a specific splice variant,
i.e. they are splice variant specific peptides (SVSPs) (Fig.3) . was not higher than that of those produced by trypsin. This result can in part be explained by the fact that many lysC peptides will be too long (>40 aa) to be detected by LC-MS analysis.
Suggested position for Fig.3 Combining peptides generated by both trypsin and lysC resulted in a modest increase in the number of isoforms with SVSPs (23%) compared to trypsin alone. These results indicate that three out of four protein isoforms cannot be uniquely identified (Fig.3 ) using these two enzymes.
Identification of splice variants in A431 cell line data
As described previously, a splice variant is identified if there is one or more peptides uniquely mapped to its sequence. To test the applicability of the method on proteomics data generated by MS-based shotgun proteomics, we used SpliceVista to analyze human cancer cell line data (A431). In the whole cell lysate, 607 unambiguous splice variants and 1680
SVSPs were identified (Table 1 ). All SVSPs reported in A431 dataset are derived from genes with multiple splice variants (see these SVSPs and their mapping output from SpliceVista in Supplementary file 4). SVSPs from single isoform genes were not counted. By subcellular fractionation, the number of unique peptides identified increased, as did the number of SVSPs and corresponding splice variants (Fig.4) . Expectedly, this data demonstrates that by using subcellular fractionation, we can increase SVSPs and splice variant identifications due to increased peptide coverage (see sequence coverage with and without subcellular fractionation in Supplementary file 2, Fig.S4 ).
Suggested position for Table 1 Suggested position for Fig.4 
Detection of differentially regulated splice variants in A431 data
The A431 dataset contains quantitative information generated by iTRAQ 8-plex labelling of samples from a gefitinib treatment time course study. Duplicate samples were taken at 2, 6
and 24h after gefitinib treatment and compared with duplicate untreated controls, and reported as ratios using the average of the controls as denominator. In the current study, we performed three different quantitative analyses on the genes with splice variants identified from this dataset (Table 1) ; gene centric analysis, protein centric analysis and splice variant centric analysis (Fig.5) (Fig.5C) . However, the other variant (37 PSMs) is the highly abundant one, and thus has the major contribution to the gene centric signal. In all three cases, the gene centric quantification result is an averaged outcome of all identified PSMs mapped to the gene and is dominated by the protein variant which contains the most PSMs. With SpliceVista, we are able to quantify splice variants Supplementary file 5). We then searched these 223 peptides in the NCBI human nonredundant protein sequence database using BLASTP (21) . Of these, 157 peptides had at least one mismatch to the sequences in the database and were therefore considered novel. One of the peptides mapping to a novel splice variant of gene PLCB2 is shown in Fig.7 .
Discovery and visualization of novel splice variant peptides in A431 data
Suggested position for Fig.7 
Splice variant specific analysis on human 4Skin hiPS cells, parental fibroblast cell lines and human ESCs
To demonstrate SpliceVista's compatibility with other proteomics datasets, the Munoz et al 2011 stem cell dataset (22) Table S3 ). The number of splice variants reported in the two mass spectrometry experiments was 390 and 397 respectively.
On average, we have found SVSPs for 7% of the identified genes in this dataset. This is comparable to the A431 cell line dataset, in which we found SVSPs for 9% of the identified genes.
The number of overlapping proteins with SVSPs identified in both MS experiments from
Munoz study was 296. Protein centric analysis of these proteins was compared to splice variant specific analysis. As shown in Fig.8A , for most proteins, protein centric analysis of Fibro/hiPS ratio is consistent with splice variant specific results. However, some proteins marked as red showed large differences of Log2(Fibro/hiPS) value between protein centric and splice centric analysis, indicating that peptides assigned to the protein may be derived from differentially regulated splice variants. The top 10 proteins ranked by Fibro/hiPS ratio differences between splice variant and protein centric analysis are shown in Fig.8B .
Suggested position for Fig.8 
Discussion
Shotgun proteomics is being widely applied in large-scale characterization of proteins due to its intrinsic ability to systematically profile the entire protein complement in the sample, both qualitatively and quantitatively. However, the lack of tools for shotgun proteomics data analysis limits the exploration of the large amount of data generated, leading to many missed protein isoforms that are relevant to specific biological events.
The herein presented tool, SpliceVista, simplifies detailed analysis of known and predicted splice variants by enabling their visualization and by mapping peptide evidence to these variants. Splice variant specific peptides (SVSPs) are the key for both identification and quantification of splice variants by SpliceVista. Hence, splice variant specific analysis is limited to the genes with SVSPs identified. Increased protein sequence coverage obtained by pre-fractionation methods at subcellular, protein or peptide level will increase the likelihood of identifying more SVSPs. However, we acknowledge the limitation of using shotgun proteomics to identify splice variants since at most one out of four splice variants can be uniquely identified even assuming 100% sequence coverage in the MS analysis.
In MS-based proteomics, the unique peptides for a gene could come from several splice variants that usually possess high sequence similarity. Unless the gene has only one splice variant, it should be noted that in gene centric analysis a gene's quantitative pattern is a mixed outcome of all present splice variants. Consequently, the quantitative pattern can thus be dominated by one or a few highly abundant splice variants, since most copies of the peptides identified come from those abundant protein variants. As shown in this study, the same problem can occur in protein centric analysis due to ambiguous assignment of peptides 
